Top

Published in:

01-12-2018

Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review

Authors: Shijie Sheng, M. Margarida Bernardo, Sijana H. Dzinic, Kang Chen, Elisabeth I. Heath, Wael A. Sakr

Published in: Cancer and Metastasis Reviews | Issue 4/2018

Abstract

The predominant cause of cancer mortality is metastasis. The major impediment to cancer cure is the intrinsic or acquired resistance to currently available therapies. Cancer is heterogeneous at the genetic, epigenetic, and metabolic levels. And, while a molecular-targeted drug may be pathway-precise, it can still fail to achieve wholesome cancer-precise toxicity. In the current review, we discuss the strategic differences between targeting the strengths of cancer cells in phenotypic plasticity and heterogeneity and targeting shared vulnerabilities of cancer cells such as the compromised integrity of membranous organelles. To better recapitulate subpopulations of cancer cells in different phenotypic and functional states, we developed a schematic combination of 2-dimensional culture (2D), 3-dimmensional culture in collagen I (3D), and mammosphere culture for stem cells (mammosphere), designated as Scheme 2D/3D/mammosphere. We investigated how the tumor suppressor maspin may limit carcinoma cell plasticity and affect their context-dependent response to drugs of different mechanisms including docetaxel, histone deacetylase (HDAC) inhibitor MS-275, and ionophore antibiotic salinomycin. We showed that tumor cell phenotypic plasticity is not an exclusive attribute to cancer stem cells. Nonetheless, three subpopulations of prostate cancer cells, enriched through Scheme 2D/3D/mammosphere, show qualitatively different drug responses. Interestingly, salinomycin was the only drug that effectively killed all three cancer cell subpopulations, irrespective of their capacity of stemness. Further, Scheme 2D/3D/mammosphere may be a useful model to accelerate the screening for curative cancer drugs while avoiding costly characterization of compounds that may have only selective toxicity to some, but not all, cancer cell subpopulations.

Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: a Cancer Journal for Clinicians, 68(1), 7–30. https://doi.org/10.3322/caac.21442.CrossRef

Global Burden of Disease Cancer, Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., et al. (2018). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2018.2706.

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer, 13(10), 714–726. https://doi.org/10.1038/nrc3599.CrossRefPubMed

Maugeri-Sacca, M., Vigneri, P., & De Maria, R. (2011). Cancer stem cells and chemosensitivity. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 17(15), 4942–4947. https://doi.org/10.1158/1078-0432.CCR-10-2538.CrossRef

McMillin, D. W., Negri, J. M., & Mitsiades, C. S. (2013). The role of tumor-stromal interactions in modifying drug response: challenges and opportunities. Nature Reviews. Drug Discovery, 12(3), 217–228. https://doi.org/10.1038/nrd3870.CrossRefPubMed

Maertens, O., McCurrach, M. E., Braun, B. S., De Raedt, T., Epstein, I., Huang, T. Q., et al. (2017). A collaborative model for accelerating the discovery and translation of cancer therapies. Cancer Research, 77(21), 5706–5711. https://doi.org/10.1158/0008-5472.CAN-17-1789.CrossRefPubMedPubMedCentral

Plowright, A. T., Ottmann, C., Arkin, M., Auberson, Y. P., Timmerman, H., & Waldmann, H. (2017). Joining forces: the Chemical Biology-Medicinal Chemistry Continuum. Cell Chemical Biology, 24(9), 1058–1065. https://doi.org/10.1016/j.chembiol.2017.05.019.CrossRefPubMed

Liu, R., Li, X., & Lam, K. S. (2017). Combinatorial chemistry in drug discovery. Current Opinion in Chemical Biology, 38, 117–126. https://doi.org/10.1016/j.cbpa.2017.03.017.CrossRefPubMedPubMedCentral

Erickson, B. K., Rose, C. M., Braun, C. R., Erickson, A. R., Knott, J., McAlister, G. C., et al. (2017). A strategy to combine sample multiplexing with targeted proteomics assays for high-throughput protein signature characterization. Molecular Cell, 65(2), 361–370. https://doi.org/10.1016/j.molcel.2016.12.005.CrossRefPubMedPubMedCentral

10.

Weeber, F., Ooft, S. N., Dijkstra, K. K., & Voest, E. E. (2017). Tumor organoids as a preclinical cancer model for drug discovery. Cell Chemical Biology, 24(9), 1092–1100. https://doi.org/10.1016/j.chembiol.2017.06.012.CrossRefPubMed

11.

Rashid, O. M., & Takabe, K. (2015). Animal models for exploring the pharmacokinetics of breast cancer therapies. Expert Opinion on Drug Metabolism & Toxicology, 11(2), 221–230. https://doi.org/10.1517/17425255.2015.983073.CrossRef

12.

Wolf, C. R., & Henderson, C. J. (1998). Use of transgenic animals in understanding molecular mechanisms of toxicity. The Journal of Pharmacy and Pharmacology, 50(6), 567–574.CrossRefPubMed

13.

Ho, B. X., Pek, N. M. Q., & Soh, B. S. (2018). Disease modeling using 3D organoids derived from human induced pluripotent stem cells. International Journal of Molecular Sciences, 19(4). https://doi.org/10.3390/ijms19040936.

14.

Ozcelikkale, A., Moon, H. R., Linnes, M., & Han, B. (2017). In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology, 9(5). https://doi.org/10.1002/wnan.1460.

15.

Goel, S., England, C. G., Chen, F., & Cai, W. (2017). Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics. Advanced Drug Delivery Reviews, 113, 157–176. https://doi.org/10.1016/j.addr.2016.08.001.CrossRefPubMed

16.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

17.

Dawson, M. A. (2017). The cancer epigenome: concepts, challenges, and therapeutic opportunities. Science, 355(6330), 1147–1152. https://doi.org/10.1126/science.aam7304.CrossRefPubMed

18.

Ricciuti, B., De Giglio, A., Mecca, C., Arcuri, C., Marini, S., Metro, G., et al. (2018). Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Medical Oncology, 35(5), 72. https://doi.org/10.1007/s12032-018-1133-4.CrossRefPubMed

19.

Hyman, D. M., Taylor, B. S., & Baselga, J. (2017). Implementing genome-driven oncology. Cell, 168(4), 584–599. https://doi.org/10.1016/j.cell.2016.12.015.CrossRefPubMedPubMedCentral

20.

Fusco, N., & Bosari, S. (2016). HER2 aberrations and heterogeneity in cancers of the digestive system: implications for pathologists and gastroenterologists. World Journal of Gastroenterology, 22(35), 7926–7937. https://doi.org/10.3748/wjg.v22.i35.7926.CrossRefPubMedPubMedCentral

21.

Piulats, J. M., Guerra, E., Gil-Martin, M., Roman-Canal, B., Gatius, S., Sanz-Pamplona, R., et al. (2017). Molecular approaches for classifying endometrial carcinoma. Gynecologic Oncology, 145(1), 200–207. https://doi.org/10.1016/j.ygyno.2016.12.015.CrossRefPubMed

22.

Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer, 12(4), 252–264. https://doi.org/10.1038/nrc3239.CrossRefPubMedPubMedCentral

23.

Patel, A., & Fong, L. (2018). Immunotherapy for prostate cancer: where do we go from here?-PART 1: prostate cancer vaccines. Oncology (Williston Park), 32(3), 112–120.

24.

Kubben, N., & Misteli, T. (2017). Shared molecular and cellular mechanisms of premature aging and aging-associated diseases. Nature Reviews. Molecular Cell Biology, 18(10), 595–609. https://doi.org/10.1038/nrm.2017.68.CrossRefPubMedPubMedCentral

25.

Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018). p53 and metabolism: from mechanism to therapeutics. Oncotarget, 9(34), 2,378,023,823. https://doi.org/10.18632/oncotarget.25267.CrossRef

26.

Proia, D. A., & Bates, R. C. (2014). Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Research, 74(5), 1294–1300. https://doi.org/10.1158/00085472.CAN-13-3263.CrossRefPubMed

27.

Thakur, M. K., Heilbrun, L. K., Sheng, S., Stein, M., Liu, G., Antonarakis, E. S., et al. (2016). A phase II trial of ganetespib, a heat shock protein 90 Hsp90 inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Investigational New Drugs, 34(1), 112–118. https://doi.org/10.1007/s10637-015-0307-6.CrossRefPubMed

28.

Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., et al. (2008). A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical Cancer Research, 14(23), 7940–7946. https://doi.org/10.1158/1078-0432.CCR-08-0221.CrossRefPubMedPubMedCentral

29.

Stratikopoulos, E. E., & Parsons, R. E. (2016). Molecular pathways: targeting the PI3K Pathway in Cancer-BET Inhibitors to the rescue. Clinical Cancer Research, 22(11), 2605–2610. https://doi.org/10.1158/1078-0432.CCR-15-2389.CrossRefPubMedPubMedCentral

30.

Medvetz, D., Priolo, C., & Henske, E. P. (2015). Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift. Molecular Cancer Research, 13(1), 3–8. https://doi.org/10.1158/1541-7786.MCR-14-0343.CrossRefPubMed

31.

Green, D. R., Galluzzi, L., & Kroemer, G. (2014). Cell biology. Metabolic control of cell death. Science, 345(6203), 1,250,256. https://doi.org/10.1126/science.1250256.CrossRef

32.

Bissell, M. J., & Hines, W. C. (2011). Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nature Medicine, 17(3), 320–329. https://doi.org/10.1038/nm.2328.CrossRefPubMedPubMedCentral

33.

Bissell, M. J., Weaver, V. M., Lelievre, S. A., Wang, F., Petersen, O. W., & Schmeichel, K. L. (1999). Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Research, 59(7 Suppl), 1757–1763s discussion 1763s–1764s.PubMed

34.

Bezecny, P. (2014). Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. Medical Oncology, 31(6), 985. https://doi.org/10.1007/s12032-014-0985-5.CrossRefPubMed

35.

Fabregat, I., Fernando, J., Mainez, J., & Sancho, P. (2014). TGF-beta signaling in cancer treatment. Current Pharmaceutical Design, 20(17), 2934–2947.CrossRefPubMed

36.

Moustakas, A., Pardali, K., Gaal, A., & Heldin, C. H. (2002). Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunology Letters, 82(1–2), 85–91.CrossRefPubMed

37.

Del Re, M., Arrigoni, E., Restante, G., Passaro, A., Rofi, E., Crucitta, S., et al. (2018). Concise review: resistance to tyrosine kinase inhibitors in non-small Cell lkung cancer: the role of cancer stem cells. Stem Cells, 36(5), 633–640. https://doi.org/10.1002/stem.2787.CrossRefPubMed

38.

Melzer, C., von der Ohe, J., & Hass, R. (2018). Concise review: crosstalk of mesenchymal stroma/stem-like cells with cancer cells provides therapeutic potential. Stem Cells. https://doi.org/10.1002/stem.2829.

39.

Pattabiraman, D. R., & Weinberg, R. A. (2014). Tackling the cancer stem cells - what challenges do they pose. Nature Reviews. Drug Discovery, 13(7), 497–512. https://doi.org/10.1038/nrd4253.CrossRefPubMedPubMedCentral

40.

D’Angelo, R. C., & Wicha, M. S. (2010). Stem cells in normal development and cancer. Progress in Molecular Biology and Translational Science, 95, 113–158. https://doi.org/10.1016/B978-0-12-385,071-3.00006-X.CrossRefPubMed

41.

Ferri, K. F., & Kroemer, G. (2001). Organelle-specific initiation of cell death pathways. Nature Cell Biology, 3(11), E255–E263. https://doi.org/10.1038/ncb1101-e255.CrossRefPubMed

42.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., et al. (2018). Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 25(3), 486–541. https://doi.org/10.1038/s41418-017-0012-4.CrossRefPubMedPubMedCentral

43.

Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., et al. (2018). Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell, 33(5), 890–904 e895. https://doi.org/10.1016/j.ccell.2018.03.017.CrossRefPubMedPubMedCentral

44.

Galluzzi, L., Bravo-San Pedro, J. M., & Kroemer, G. (2015). Ferroptosis in p53-dependent oncosuppression and organismal homeostasis. Cell Death and Differentiation, 22(8), 1237–1238. https://doi.org/10.1038/cdd.2015.54.CrossRefPubMedPubMedCentral

45.

Garg, A. D., & Agostinis, P. (2017). Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunological Reviews, 280(1), 126–148. https://doi.org/10.1111/imr.12574.CrossRefPubMed

46.

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 149(5), 1060–1072. https://doi.org/10.1016/j.cell.2012.03.042.CrossRefPubMedPubMedCentral

47.

Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., et al. (2009). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 138(4), 645–659. https://doi.org/10.1016/j.cell.2009.06.034.CrossRefPubMedPubMedCentral

48.

Mai, T. T., Hamai, A., Hienzsch, A., Caneque, T., Muller, S., Wicinski, J., et al. (2017). Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nature Chemistry, 9(10), 1025–1033. https://doi.org/10.1038/nchem.2778.CrossRefPubMedPubMedCentral

49.

Bernardo, M. M., Kaplun, A., Dzinic, S. H., Li, X., Irish, J., Mujagic, A., et al. (2015). Maspin expression in prostate tumor cells averts stemness and stratifies drug sensitivity. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-15-0234.

50.

Ohkubo, S., Dalla Via, L., Grancara, S., Kanamori, Y., Garcia-Argaez, A. N., Canettieri, G., et al. (2018). The antioxidant, aged garlic extract, exerts cytotoxic effects on wild-type and multidrug-resistant human cancer cells by altering mitochondrial permeability. International Journal of Oncology, 53(3), 1257–1268. https://doi.org/10.3892/ijo.2018.4452.CrossRefPubMed

51.

Ogita, A., Fujita, K., & Tanaka, T. (2012). Enhancing effects on vacuole-targeting fungicidal activity of amphotericin B. Frontiers in Microbiology, 3, 100. https://doi.org/10.3389/fmicb.2012.00100.CrossRefPubMedPubMedCentral

52.

Feinberg, A. P. (2007). Phenotypic plasticity and the epigenetics of human disease. Nature, 447(7143), 433–440. https://doi.org/10.1038/nature05919.CrossRefPubMed

53.

Holzel, M., Bovier, A., & Tuting, T. (2013). Plasticity of tumor and immune cells: a source of heterogeneity and a cause for therapy resistance. Nature Reviews. Cancer, 13(5), 365–376. https://doi.org/10.1038/nrc3498.CrossRefPubMed

54.

Jia, D., Jolly, M. K., Kulkarni, P., & Levine, H. (2017). Phenotypic plasticity and cell fate decisions in cancer: insights from dynamical systems theory. Cancers (Basel), 9(7). https://doi.org/10.3390/cancers9070070.

55.

Bernardo, M. M., Meng, Y., Lockett, J., Dyson, G., Dombkowski, A., Kaplun, A., et al. (2011). Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes & Cancer, 2(11), 1009–1022. https://doi.org/10.1177/1947601912440170.CrossRef

56.

Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A., Neveu, M., Sheng, S., et al. (1994). Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science, 263(5146), 526–529.CrossRefPubMed

57.

Dzinic, S. H., Bernardo, M. M., Li, X., Fernandez-Valdivia, R., Ho, Y. S., Mi, Q. S., et al. (2017). An essential role of maspin in embryogenesis and tumor suppression. Cancer Research, 77(4), 886–896. https://doi.org/10.1158/0008-5472.CAN-16-2219.CrossRefPubMed

58.

Lockett, J., Yin, S., Li, X., Meng, Y., & Sheng, S. (2006). Tumor suppressive maspin and epithelial homeostasis. [Review]. Journal of Cellular Biochemistry, 97(4), 651–660. https://doi.org/10.1002/jcb.20721.CrossRefPubMed

59.

Bernardo, M. M., Dzinic, S. H., Matta, M. J., Dean, I., Saker, L., & Sheng, S. (2017). The Opportunity of precision medicine for breast cancer with context-sensitive tumor suppressor maspin. Journal of Cellular Biochemistry, 118(7), 1639–1647. https://doi.org/10.1002/jcb.25969.CrossRefPubMedPubMedCentral

60.

Kaplun, A., Dzinic, S., Bernardo, M., & Sheng, S. (2012). Tumor suppressor maspin as a rheostat in HDAC regulation to achieve the fine-tuning of epithelial homeostasis. Critical Reviews in Eukaryotic Gene Expression, 22(3), 249–258.CrossRefPubMedPubMedCentral

61.

Li, X., Yin, S., Meng, Y., Sakr, W., & Sheng, S. (2006). Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Research, 66(18), 9323–9329. https://doi.org/10.1158/0008-5472.CAN-06-1578.CrossRefPubMed

62.

Zhang, M., Hendrix, M. J. C., Pemberton, P. A., Sakr, W. A., & Sheng, S. (2017). An Essential Role of Maspin in Embryogenesis and Tumor Suppression-Response. Cancer Research, 77(18), 5208–5210. https://doi.org/10.1158/0008-5472.CAN-17-1254.CrossRefPubMed

63.

Biliran Jr., H., & Sheng, S. (2001). Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Research, 61(24), 8676–8682.PubMed

64.

Jiang, N., Meng, Y. H., Zhang, S. L., Mensah-Osman, E., & Sheng, S. J. (2002). Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene, 21(26), 4089–4098. https://doi.org/10.1038/sj.onc.1205507.CrossRefPubMed

65.

Cher, M. L., Biliran, H. R., Bhagat, S., Meng, Y. H., Che, M. X., Lockett, J., et al. (2003). Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proceedings of the National Academy of Sciences of the United States of America, 100(13), 7847–7852. https://doi.org/10.1073/pnas.1331360100.CrossRefPubMedPubMedCentral

66.

Domingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., Rodriguez-Barrueco, R., et al. (2012). Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell, 22(3), 373–388. https://doi.org/10.1016/j.ccr.2012.07.016.CrossRefPubMedPubMedCentral

67.

Hwang, C. (2012). Overcoming docetaxel resistance in prostate cancer: a perspective review. Therapeutic Advances in Medical Oncology, 4(6), 329–340. https://doi.org/10.1177/1758834012449685.CrossRefPubMedPubMedCentral

68.

O’Neill, A. J., Prencipe, M., Dowling, C., Fan, Y., Mulrane, L., Gallagher, W. M., et al. (2011). Characterization and manipulation of docetaxel resistant prostate cancer cell lines. Molecular Cancer, 10, 126. https://doi.org/10.1186/1476-4598-10-126.CrossRefPubMedPubMedCentral

69.

Li, X. H., Chen, D., Yin, S. P., Meng, Y. H., Yang, H. J., Landis-Piwowar, K. R., et al. (2007). Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells. Journal of Cellular Physiology, 212(2), 298–306. https://doi.org/10.1002/Jcp.21102.CrossRefPubMed

70.

Tahmatzopoulos, A., Sheng, S., & Kyprianou, N. (2005). Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene, 24(34), 5375–5383. https://doi.org/10.1038/sj.onc.1208684.CrossRefPubMedPubMedCentral

71.

Zhang, Y., Liu, L., Li, F., Wu, T., Jiang, H., Jiang, X., et al. (2017). Salinomycin Exerts Anticancer Effects on PC-3 Cells and PC-3-Derived Cancer Stem Cells In Vitro and In Vivo. BioMed Research International, 4, 101–653. https://doi.org/10.1155/2017/4101653.CrossRef

Title: Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review
Authors: Shijie Sheng
M. Margarida Bernardo
Sijana H. Dzinic
Kang Chen
Elisabeth I. Heath
Wael A. Sakr
Publication date: 01-12-2018
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2018
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-018-9767-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Pleiotropic effects of moonlighting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in cancer progression, invasiveness, and metastases

Cancers of the eye

Perspectives on the role of brain cellular players in cancer-associated brain metastasis: translational approach to understand molecular mechanism of tumor progression

Roles of the mitochondrial genetics in cancer metastasis: not to be ignored any longer

Developing TRAIL/TRAIL death receptor-based cancer therapies

Biography—Stephanie Tucker

Keynote webinar | Spotlight on antibody–drug conjugates in cancer